

Costs Associated With Managing Fat Malabsorption With Enteral Nutrition

Any/all may be applicable


Add fiber

Add fiber as an adjunctive to standard EN formulas or formulas with fiber¹



Reduce feeding

Reduce or stop enteral nutrition¹⁻³



Change formulas

From polymeric to more expensive semi-elemental/elemental formulas⁴

Add pancreatic enzymes⁵



Change modalities

Initiate parenteral nutrition¹



Management of GI Symptoms



Resource use, including nursing time, laundry and cleaning services, infection control, supplies, and others.⁶⁻⁸

RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. RELiZORB is for use with enteral feeding only; do not connect to intravenous or other medical tubing. Medications should not be administered through RELiZORB. Please see Instructions for Use for full safety information at www.relizorb.com.

RELiZORB® 
(iMMOBILIZED LIPASE) CARTRIDGE



Pancreatic enzyme
(lipase) cartridge

The First and Only Option
for Hydrolyzing Fats in
Enteral Nutrition

References: 1. McClave SA, et al. Am J Gastroenterol. 2016;111(3):315-334; quiz 335. 2. McClave SA, et al. J Parenter Enteral Nutr. 2016;40(2):159-211. 3. Blumenstein I, et al. World J Gastroenterol. 2014;20(26):8505-24. 4. Curry AS, et al. Clinicoecon Outcomes Res. 2018;10:293-300. 5. Nguyen DL. Am J Manag Care. 2017;23(12 suppl):S210-S219. 6. Polage CR, et al. Clin Infect Dis. 2012;55(7):982-9. 7. Tirlapur N, et al. Sci Rep. 2016;6:24691. 8. Olson B. Poster presented at: HQI Annual Conference; October 28-30, 2018; Huntington Beach, CA.

RELiZORB vs Pancreatic Enzyme Practice in Enteral Nutrition

	RELiZORB	Pancreatic Enzymes (Creon, Viokase, Zenpep)**
FDA Approved/ Cleared for Use in Enteral Feeding	✓ RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula ¹	✗ Not Approved for use with Enteral Nutrition ^{4,5}
Clinical Evidence in Enterally-Fed Patients	<ul style="list-style-type: none"> ✓ 2.8 fold increase absorption of key Omega-3 fatty acids after a single RELiZORB use and normalized fat absorption over 90 days ✓ >50% of patients reported a decrease in the frequency of some GI events^{2,3} 	<ul style="list-style-type: none"> ✗ No confirmed efficacy; no evidence of diarrhea reduction; limited evidence of fat absorption^{2,5} ✗ Clinical trials excluded enterally fed patients^{4,5}
Safety	✓ Two trials showed safety of short and long term use with Enteral Nutrition ^{2,3}	✗ No safety data for patients on Enteral Nutrition, unsure how it impacts patients
Convenience	<ul style="list-style-type: none"> ✓ Proven continuous fat hydrolysis ✓ Easy set-up and use 	<ul style="list-style-type: none"> ✗ Active for 45-60 mins after administration^{4,8} ✗ Difficult to administer^{4,5} ✗ Risk of clogging and potential increased staff burden^{4,5,9}

RELiZORB® 
(IMMOBILIZED LIPASE) CARTRIDGE



Pancreatic enzyme
(lipase) cartridge

The First and Only Option
for Hydrolyzing Fats in
Enteral Nutrition

*Wholesale Acquisition Price 6/1/19

**Creon, Viokase and Zenpep are registered trademarks of their respective owners.

References: **1.** RELiZORB [instructions for use]. Newton, MA: Alcresta Therapeutics; 2018. **2.** Freedman S, et al. J Pediatr Gastroenterol Nutr. 2017;65(1):97-101. **3.** Stevens J, et al. J Pediatr Gastroenterol Nutr. 2018;67(4):527-532. **4.** Nguyen DL. Am J Manag Care. 2017;23(12 suppl):S210-S219. **5.** Schwarzenberg SJ, et al. J Cyst Fibros. 2016;15(6):724-735. **6.** Cystic Fibrosis Foundation Website. <https://www.cff.org/Life-With-CF/Daily-Life/Fitness-and-Nutrition/Nutrition/Taking-Care-of-Your-Digestive-System/Enzymes/>. Accessed April 19, 2018. **7.** Creon [safety data sheet]. North Chicago, IL: AbbVie Inc; 2015.



RELiZORB, the Alcresta capstone, and Alcresta Therapeutics are registered trademarks of Alcresta Therapeutics, Inc.

©2019 Alcresta Therapeutics, Inc. All rights reserved.

Patents: <http://www.alcresta.com/patents> REL19-296